fbpx

Category: Highlights

Contact Us

Contact us on 1300 369 772 Monday to Friday, business hours

Share this page

PSA welcomes SA’s nation-leading vaccination scope for pharmacists and calls on other states to follow

6 February 2025

 

The Pharmaceutical Society of Australia (PSA) commends the South Australian Government for its decision to remove the regulatory shackles holding pharmacists back from fully using their skills and expertise to protect people from vaccine-preventable diseases.

 

As announced today by the Minister for Health and Wellbeing Chris Picton MP, effective immediately, South Australian pharmacist immunisers can authorise and administer any vaccine within their individual scope of practice, including for the first time travel health vaccines for cholera, rabies and typhoid.

 

Similarly, the government has removed unnecessary red tape regulating age cohorts which has constrained and disincentivised service provision by pharmacists.

 

PSA South Australia and Northern Territory President Dr Manya Angley FPS celebrated the announcement.

 

“From today, South Australian pharmacists will be authorised to prescribe and administer vaccines from the same vaccine formulary as every other vaccinator – the Australian Immunisation Handbook,” Dr Angley said.

 

“This will dramatically improve access and convenience for South Australians. No longer will patients need to wait for pharmacists to review unnecessarily complex legal authority to before safely authorising and administering recommended vaccines, including travel health vaccines

 

“South Australia is leading the nation in scope of pharmacist-administered vaccines, a fact that we should be very proud of.

 

“I thank Minister Picton for his confidence in our profession in supporting a more sophisticated and contemporary approach to pharmacist scope of practice. PSA has advocated for today’s changes for a number of years. I am confident in saying that today, South Australia is the envy of our pharmacist vaccinator colleagues in every other jurisdiction across the country.

 

Adding support to the announcement, PSA National President Associate Professor Fei Sim FPS heralded the reforms ‘nation-leading’ and called for other jurisdictions to adopt the South Australian approach.

 

“Today’s announcement in South Australia means that pharmacists will be able to prescribe and administer vaccines consistent with their skills and knowledge, rather than be held back by regulation. Regulation should enable, rather than restrict good health care provision. This approach will unlock a new level of care, and should be the standard all other states and territories aspire to,” A/Prof Sim said.

 

“This is a significant and sensible step forward to improve Australians’ access to healthcare which will strengthen our healthcare system’s capacity.

 

“PSA is advocating to regulators in every other Australian jurisdiction urging for alignment of these regulatory changes in each jurisdiction to unleash the potential of pharmacists in protecting the health and wellbeing of Australians,” A/Prof Sim concluded.

​

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Share this page
Share this page

PSA applauds Northern Territory’s expansion of pharmacist authority to prescribe and administer a wider range of vaccines

3 February 2025

 

The Pharmaceutical Society of Australia (PSA) commends the Northern Territory Government for its decision to further expand the scope of pharmacist-administered vaccination.

 

Effective immediately, pharmacists in the Territory are authorised to prescribe and administer a wider range of vaccines, including private market vaccines such as shingles and whooping cough vaccines when not covered under the National Immunisation Program (NIP).

 

Additionally, from today, NT pharmacists can also administer the Respiratory Syncytial Virus vaccine (RSV) at no cost to patients through the NIP during pregnancy from 28 to 36 weeks’ gestation.

 

PSA SA/NT President Dr Manya Angley FPS lauded the initiative, stating, “This development is a significant advancement in public health, enhancing access to essential vaccines for Territorians.

 

“The current measles alert in the NT is a timely reminder of the importance of staying up-to-date with vaccination and catching up on missed doses,” she continued.

 

“By empowering pharmacists to authorise and administer an expanded range of vaccines, including NIP vaccines like RSV, the Northern Territory Government is leveraging the expertise of pharmacists to improve healthcare delivery, particularly in remote and underserved communities”, Dr Angley said.

 

PSA has long advocated for the expansion of pharmacists’ roles in immunisation, recognising the potential to increase vaccination rates and reduce the burden on other healthcare providers. This change will make it easier for patients to access life-saving vaccines closer to home at their convenience.

 

PSA National President, Associate Professor Fei Sim FPS, encouraged other Australian states and territories to follow the Northern Territory’s leadership in this area.

 

“Expanding pharmacists’ vaccination authority nationwide will improve vaccination accessibility and immunisation coverage across the country. PSA urges all jurisdictions to consider similar measures, removing barriers such as limitations on vaccine, patient age, funding and location of vaccination,” A/Prof Sim concluded.

 

PSA remains committed to supporting pharmacists in delivering high-quality and accessible healthcare services and will continue to advocate for policies that optimise the role of pharmacists in Australia’s health system.

​

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

 

Note: The Professional Practice Standards defines prescribing as ‘an iterative process involving the steps of information gathering, clinical decision-making, communication and evaluation that results in the initiation, continuation or cessation of a medicine. This may differ from the definition provided in the legislation governing the use of medicines in each jurisdiction. Health professionals are advised to review the legislation in effect in the state or territory in which they practice to ensure they understand their legal authorisation to prescribe medicines’.

 

The updated SSTP authorises pharmacists to initiate and administer listed vaccines. This authority does not extend to the issuing of a prescription for dispensing and/or administration of another health practitioner.

 

Share this page
Share this page

Changes to paracetamol scheduling will reduce risk of harm to children and adolescents

31 January 2025

 

Paracetamol is one of the medicines most frequently responsible for hospital admissions due to poisoning, a new report from the peak body for Australian pharmacists has found, with approximately 16 per cent of pharmaceutical poisoning hospital admissions in children under five years of age being attributed to paracetamol.

 

The Medicine safety: Children and adolescent care report released by the Pharmaceutical Society of Australia today further reveals that an estimated 93 children present to Australia’s emergency departments each day due to medicine-related problems, with approximately 40 admitted to hospitals. At least half of these incidents are preventable.

 

The report comes as federal government changes to paracetamol pack sizes come into effect, limiting the amount of paracetamol stored in Australian households and reducing the risk of intentional and unintentional harm including in children and adolescents. PSA joined Assistant Minister for Health and Aged Care Ged Kearney at Westgarth Pharmacy in Melbourne to launch the report and discuss paracetamol changes.

 

Effective from 1 February 2025, general sale pack sizes available from supermarkets or grocery stores will be reduced from 20 to 16 tablets, and Pharmacy Medicine packs will be limited to 50 tablets, with larger packs requiring pharmacist supervision (Pharmacist Only Medicine).

 

Paracetamol tablets in general sale packs and Pharmacy Medicine packs will also be required to be in blister packaging. Blister packaging can reduce overdose and impulsive attempts to self-harm by slowing the consumption of multiple tablets or capsules.

 

As the peak body for all Australian pharmacists, PSA strongly supports the move which will reduce the risk of overdose and poisoning, but there is more to be done.

 

 

 

Quotes attributable to PSA National President Associate Professor Fei Sim FPS:

 

“The sobering reality is that we are leaving our kids vulnerable to harm, particularly when it comes to common medicines around the house.

 

“By limiting the maximum pack sizes of paracetamol, we are opening the door to have a conversation about the risks and benefits of these medicines – both in the pharmacy and at home – and take steps as a community to promote the safe use of medicines.

 

“By involving pharmacists in the supply of larger paracetamol pack sizes, we strike the right balance between access and safety, giving pharmacists and pharmacy assistants the opportunity to help patients manage their pain effectively while reducing the risk of misuse and harm.

 

“As the peak body for all pharmacists in all areas of practice, PSA continues to advocate for pharmacists to be further empowered in their roles as medicine safety experts. This includes the recommendations PSA makes in our report, from implementing a national reporting system for medicine safety incidents, to increasing the availability of pharmacists in children’s hospital wards.

 

“It takes all of us, across health professions, communities and policymakers, to make a difference to the children and adolescents who rely on our care.”

 

Quotes attributable to Assistant Minister for Health and Aged Care, Ged Kearney MP:

 

“Each year in Australia around 225 people are hospitalised with liver injury and 50 people die from paracetamol overdose. To think of so many young lives lost is heartbreaking.

 

“The TGA’s decision to limit the size of paracetamol packs struck a balance between protecting young Australians from harm while also ensuring those in pain can access the medicine. My thanks to the TGA for its sensible and measured decision, and to the pharmacists and retailers around the country who have responded so robustly.”

 

Key findings from the Medicine safety: Children and adolescent care report:

  • Medicine-related problems in children and adolescents cost the Australian economy at least $130 million annually.
  • An estimated 93 children present to Australia’s emergency departments each day due to medicine-related problems, with approximately 40 admitted to hospitals. At least half of these incidents are preventable.
  • Paracetamol is responsible for approximately 16 per cent of pharmaceutical poisoning hospital admissions in children under five years of age.
  • Poisoning by non-opioid analgesics, antipyretics or antirheumatics was the leading cause of admission, with paracetamol accounting for at least 85% of the cases within this group.

 

The full Medicine safety: Children and adolescent care report is available here.

 

PSA media contact: Georgia Clarke M: 0480 099 798 E: georgia.clarke@psa.org.au

Assistant Minister Kearney media contact: Isabella Tilley 0414 894 040

Share this page
Share this page

PSA set to negotiate and sign new pharmacy programs agreement

31 January 2025

 

The Pharmaceutical Society of Australia (PSA) are set to negotiate the first dedicated agreement on pharmacy programs with the Australian Government. PSA will be signatory to this agreement.

 

The agreement will cover a range of pharmacy programs that no longer sit within the 8th Community Pharmacy Agreement, including but not limited to medication management programs (including Home Medicines Reviews and Residential Medication Management Reviews), Aboriginal and Torres Strait Islander specific programs, and rural support programs that encompass pharmacists in a range of practice areas.

 

The new agreement will see PSA and the Commonwealth work together, alongside other pharmacy stakeholders, to strengthen programs that pharmacists deliver across the health system.

 

PSA National President Associate Professor Fei Sim FPS said the agreement was an opportunity to reform programs to ensure they are fit-for-purpose, now and into the future.

 

“PSA is the recognised peak body for all pharmacists, in all areas of practice across our health system. This agreement is an opportunity to reform program rules and funding arrangements to maximise the impact of pharmacists across the health sector,” Associate Professor Sim said.

 

“In negotiating a standalone agreement with the Australian Government, we are advocating for the changes we have long known need to happen, allowing pharmacists to best serve our communities.

 

“Members will be aware that following PSA’s advocacy, the government confirmed in late 2024 that these programs would have ongoing funding beyond the current financial year. Now that there is security of funding for these programs, our focus turns to removing the barriers that have prevented pharmacists from playing a greater role in patient care.”

 

As signatory to the new agreement, PSA will be seeking feedback from pharmacists and stakeholders on program arrangements and barriers.

 

“I encourage every pharmacist involved in these programs to have their say so that we can provide a full picture of the barriers, challenges and opportunities for pharmacists to provide better care for patients.

 

“PSA looks forward to continuing our work with the federal government to secure a stronger pharmacy profession now and into the future,” Associate Professor Sim concluded.

 

PSA consultant pharmacist adviser Debbie Rigby FPS also welcomed the announcement.

 

“As the home for credentialed pharmacists, it’s important that PSA is the organisation leading these discussions,” Ms Rigby said.

 

“I’m excited to be part of PSA’s team, advocating for improvements to these programs. As someone with a deep understanding of the current programs, I am committed to raising awareness of the benefits of these programs and further enhancing outcomes for patients.”

​

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Share this page
Share this page

Nearly 34,000 children presenting to emergency departments each year due to medicine problems, new report finds

31 January 2025

 

An estimated 93 children present to Australia’s emergency departments each day due to medicine-related problems, with approximately 40 admitted to hospitals, according to a new report from the peak body for Australian pharmacists.

 

The Medicine safety: Child and adolescent care report released by the Pharmaceutical Society of Australia today reveals the extent of medicine-related problems in children and adolescents, costing the Australian economy at least $130 million each year.

 

In the past six months alone, approximately 120,000 Australian children under 14 years old have experienced an adverse event due to medicines.

 

The report calls for Australia’s health system to be better equipped to deal with medicine safety challenges, with recommendations for action including the implementation of a national incident reporting and learning system, so that when children are harmed by medicines, health professionals and systems learn how to prevent another child suffering the same harm. This would bring Australia in line with many of our international peers, including Canada who have had the Assurance and Improvement in Medication Safety (AIMS) program in place since 2019.

 

Further recommendations also call for increased availability of pharmacists in paediatric wards of hospitals, as well as mandatory indication on prescriptions for children and adolescents, and mandatory manual dose checks during dispensing of paediatric prescriptions.

 

PSA National President Associate Professor Fei Sim FPS said the report’s findings painted a sobering reality of medicine use in Australia’s children and adolescents, showing the urgent need for reform.

 

“As the peak body for all pharmacists in all areas of practice, PSA continues to advocate for pharmacists to be further empowered in their roles as medicine safety experts.

 

“Our health system is failing children and adolescents. As a health community, we must commit to doing better, but we also need to be given the resources and tools to do better. Pharmacists are critical to ensure the safe use of medicines and must be supported to do so.

 

“That means adequately staffing children’s hospital wards with the expertise of pharmacists, investing in systems that capture the data needed for evidence-based policy, and improving the quality use of medicines whenever medicines are used.

 

“It takes all of us, across all areas of practice and indeed across all health professions, to make a difference to the children and adolescents who rely on our care,” Associate Professor Sim concluded.

 

The full Medicine safety: Child and adolescent care report is available at www.psa.org.au/medicine-safety-child-adolescent-care-report/

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Share this page
Share this page

PSA announce intent to acquire Australasian College of Pharmacy

28 January 2025

 

The Pharmaceutical Society of Australia (PSA) Board has today announced plans to acquire the Australasian College of Pharmacy, further growing PSA’s leadership in education and training for pharmacists, pharmacy assistants, and technicians.

 

The Australasian College of Pharmacy (the College) is a member-based organisation developing and delivering education, training, and research programs to pharmacists and pharmacy assistants since 1976.

 

The decision to acquire the College is part of the PSA Board’s broader plan to maximise member value through growth, expanding education opportunities for the profession, and securing a long-term, sustainable future for PSA as the premier training and education provider for pharmacists, pharmacy assistants and technicians.

 

PSA’s acquisition of the College builds on its long history of high-quality, nation-leading education and training for pharmacists, allowing further investment in professional and practice support for members.

 

The PSA Board has carefully considered the impact of acquiring the College, and alongside independent advice from third-party experts the Board is confident this is the right path forward for PSA, its members, and the broader profession.

 

National President and Chair of the PSA Board Associate Professor Fei Sim FPS said the acquisition will be a transformational opportunity to grow PSA’s industry-leading education and workforce development offer.

 

“The PSA Board’s strategic decision to acquire the Australasian College of Pharmacy secures a long-term future for pharmacy workforce education. It puts PSA in a stronger representative and financial position to support and advocate for our members during this pivotal time of practice change in pharmacy,” Associate Professor Sim said.

 

“Along with the PSA Board, I fully understand the challenges pharmacists are facing, as we transition to full scope of practice and our roles become increasingly demanding.

Growing our footprint within pharmacy education means we can further invest in not only education, but also the professional and practice support PSA provides. As our profession continues to mature, this unity will provide the necessary strength our profession needs at this critical time of change to fully utilise our skills and expertise.

 

“We are ambitious about our future growth as an organisation, as the peak education and representative body for all pharmacists across all areas of practice.

 

“We look forward to being able to provide even more education opportunities and support to pharmacists, pharmacy assistants and technicians, strengthening our pharmacy profession and ultimately improving care for our patients,” Associate Professor Sim concluded.

 

ACP Chief Executive Officer Amanda Seeto said the College and the PSA had always shared a commitment to providing contemporary education and training in a format that is accessible, efficient, and most importantly – highly relevant to Australian pharmacists.

 

“This exciting and pragmatic change maximises the focus on world-leading professional development for Australian pharmacists, no matter their practice setting or career stage.

 

“The move will set our sector up for success, at a time when pharmacy is becoming an increasingly valued frontline health service.”

 

PSA members are set to vote on matters relating to the acquisition at an upcoming meeting.

 

​

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Share this page
Share this page

PSA congratulates Anna Barwick MPS on being awarded the Medal of Order of Australia (OAM)

26 January 2025

 

The Pharmaceutical Society of Australia (PSA) congratulates NSW pharmacist Member Mrs Anna Barwick MPS on being awarded the Medal of Order of Australia (OAM) in the 2025 Australia Day Honours.

 

Ms Barwick founded PharmOnline, an innovative platform which connects Australian patients living in remote areas with pharmacy services. A pharmacy academic from Walcha, NSW, she previously served on PSA’s NSW Branch Committee, including holding the role of vice-president from 2014-2020.

 

PSA National President Associate Professor Fei Sim FPS acknowledged Anna’s enormous contribution to pharmacy profession.

 

“Anna is a truly outstanding pharmacist. A pioneer of innovation, she has consistently transformed access to care in her community and beyond. I have been privileged to see first-hand Anna’s work, and hope that others are as inspired and energised as I am by her contribution to the community and to the next generation of pharmacists.” A/Prof Sim said.

 

“Long recognised by the profession, having won PSA’s Pharmacy Shark Tank award in 2021 and NSW Pharmacist of the Year in 2021, I am excited to see her achievements recognised on the national stage.”

 

“On behalf of PSA and the pharmacy profession, I sincerely congratulate Anna on this well-deserved recognition.”

 

Learn more about Anna’s work in Australian Pharmacist.

Share this page
Share this page

PSA announces Community of Specialty Interest for Hospital Pharmacists

21 January 2025

 

The Pharmaceutical Society of Australia (PSA) announces its Hospital Pharmacy Practice Community of Specialty Interest (CSI), a new forum focussed on strengthening support for pharmacists practising in Australia’s hospitals.

 

The Hospital Pharmacy Practice CSI is dedicated to improving care in hospitals, including embedding pharmacists within healthcare teams, facilitating pharmacist prescribing within collaborative care models and improving pharmacist stewardship of medicine management to improve outcomes of transitions of care.

 

Led by an experienced team of hospital pharmacy leaders, the CSI addresses emerging practice needs through collaboration and knowledge sharing.

 

Hospital pharmacists now have access to a members-only Facebook group where they can connect with the CSI, with a dedicated online webinar to be hosted in early 2025.

 

Leading hospital pharmacist Professor Michael Dooley MPS has been appointed to chair the new CSI.

 

On behalf of the PSA Board, National President Associate Professor Fei Sim FPS welcomed and thanked Professor Michael Dooley for leading this important work.

 

“The establishment of this CSI is a testament to PSA’s ongoing commitment to all pharmacists as the peak body representing pharmacists across all areas of practice”

 

PSA Chief Executive Officer Adjunct Associate Professor Steve Morris emphasised the importance of leadership in evolving areas of pharmacy practice.

 

“PSA has heard members’ feedback and are moving to provide more support for pharmacists practising in hospitals. We’re excited to welcome Professor Dooley as Chair of the Hospital Pharmacists CSI, where he will work with us to develop a package of support tailored to the needs of pharmacists practicing in this setting.

 

“Hospital pharmacists have unique experiences in practice and face evolving unique challenges. PSA is proud to continue strengthening our representation of hospital pharmacists with the extensive experience and expertise of Michael and the CSI leadership group.”

 

Hospital Pharmacy Practice CSI Chair Professor Michael Dooley MPS said: “Every day in Australia there are over 24,000 presentations to emergency departments   30,000 admissions into hospital and 100,000 patients receiving non-admitted care through hospitals. Pharmacists have a crucial role in the care of these patients especially as they transition between settings and services.

 

“I am excited to be part of this great initiative and look forward to working alongside such an experienced team at the PSA to help inform and shape the future for hospital pharmacy practice.”

 

The Hospital Pharmacy Practice CSI is an exclusive community for PSA members. The CSI leadership team are set to host a webinar in early 2025 to formally introduce the CSI and its program of work.

 

Chaired by Professor Michael Dooley, the Hospital Pharmacy Practice CSI is led by:

  • Choi-Ling Batten
  • Professor Ian Coombes
  • Lauren Fraser
  • Hannah Knowles
  • Associate Professor Sue Kirsa
  • Richard Marotti
  • Professor Lisa Nissen
  • Associate Professor Bhavini Patel
  • Prasin Rodrigues

 

For more information and to join the new community, visit www.psa.org.au/communities-of-specialty-interest/hospital-pharmacists-csi/

 

About Hospital Pharmacy Practice CSI Chair Professor Michael Dooley MPS

 

Professor Michael Dooley is an experienced clinical pharmacist and leader. His career has focused in the acute healthcare sector and has spanned special clinical roles in oncology through to senior leadership positions within health services. He has led a wide range of initiatives progressing improvement in medication use and clinical pharmacy practice in Australia including development of profession standards of practice and formal training programs. 

 

Having practised across cardiology and oncology before becoming a senior oncology pharmacist at the Peter MacCallum Cancer Centre and then appointed as Director of Pharmacy He undertook research into medicine use in oncology which became the focus of his PhD, and in 2005 he became the Director of Pharmacy at Alfred Health in Melbourne and the inaugural Chair of Clinical Pharmacy of the Faculty of Pharmacy and Pharmaceutical Sciences of Monash University. In this role he has led the development and implementation of a range of innovative pharmacist led practice models spanning inpatient and ambulatory settings.

 

Professor Dooley contributes to many national and local professional committees and working parties related to improving the delivery of quality health care services. Michael has also worked with many health services within Australia and overseas in implementing services to improve medication use, transition of care and uptake of innovative pharmacy services.

 

Professor Dooley is a former President of the Society of Hospital Pharmacists (SHPA).

​

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

​

Share this page
Share this page

NAPSA Wildcard Pharmacy Student of the Year 2025 Announced

20 January 2025

 

The Pharmaceutical Society of Australia (PSA) is proud to announce Brielle Geard from the University of Tasmania as the 2025 NAPSA Wildcard Pharmacy Student of the Year, awarded at NAPSA Congress in Brisbane.

 

The Pharmacy Student of the Year (PSOTY) competition showcases the top pharmacy students in Australia, celebrating their exceptional skills, knowledge, and dedication to the pharmacy profession. The Wildcard category provides students who did not win their local competition another opportunity to compete and demonstrate their capabilities on a national stage at PSA25 in August.

 

PSA National President Associate Professor Fei Sim FPS congratulated Brielle Geard on their outstanding achievement.

 

“The PSOTY competition is a valuable platform for pharmacy students to showcase their clinical knowledge, communication skills, and professionalism. Brielle has demonstrated excellence in all these areas, and this award highlights their potential as a future leader in the pharmacy profession,” Associate Professor Sim said.

 

The Wildcard competition involved a rigorous assessment process, with participants judged on their ability to solve complex clinical scenarios while effectively communicating with patients and healthcare teams. Brielle stood out for their exceptional communication skills and knowledge.

 

Ms Geard will now progress to the final round of the PSOTY competition, to be held at PSA25 in Sydney, where they will compete against other state and territory winners for the coveted Pharmacy Student of the Year title.

 

PSA acknowledges and thanks the National Australian Pharmacy Students’ Association (NAPSA) for its ongoing support in the Pharmacy Student of the Year competition, which nurtures and inspires the next generation of pharmacists.

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Share this page
Share this page

Pill testing will save lives this summer

23 December 2024

 

The Pharmaceutical Society of Australia (PSA) welcomes boosted accessibility of pill testing this summer, with New South Wales joining Victoria and the ACT in offering pill testing services.

 

PSA supports drug checking as a method of harm reduction and broadly supports the availability of drug checking services at events like music festivals and at fixed sites.

 

A 2023 evaluation of ACT drug checking service CanTEST revealed only 53% of substances tested matched the expected drug. For those where an additional drug, a different drug or an inconclusive result was found, one-third reported that they ‘definitely will not’ use the drug.1

 

PSA National President Associate Professor Fei Sim FPS said PSA has long advocated for expanded drug checking services, with harm minimisation being an essential principle of Australia’s National Drug Strategy since 1985.

 

“Having drug checking services available is key to reducing the harm of illicit substances,” Associate Professor Sim said.

 

“Drug checking or pill testing is not about telling consumers ‘this substance is safe’, but about allowing them to make an informed decision about the risks of the substances they have.

 

“Every summer we see young people lose their lives at events around the country because they didn’t know what was in the drugs they were taking.

 

“The evidence is overwhelming – pill testing and drug checking saves lives.

 

“But importantly it is also an opportunity for a health professional to provide tailored support and information on illicit drug use and harm.

 

“PSA supports further expansion of drug testing, further investing in trials and research to support evidence-based, informed decisions about pill testing.”

 

1 Olsen A, Baillie G, Bruno R, McDonald D, Hammoud M, Peacock A (2023). CanTEST Health and Drug Checking Service Program Evaluation: Final Report. Australian National University: Canberra, ACT

 

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Share this page

In the spirit of reconciliation, the Pharmaceutical Society of Australia (PSA) acknowledges the Traditional Custodians of Country throughout Australia and their connections to land, sea and community. We pay our respect to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today. We recognise that Aboriginal and Torres Strait Islander peoples were our first pharmacists.

CONTACT US | TERMS OF USE | PRIVACY

© 2025 Pharmaceutical Society of Australia Ltd. All rights reserved.